Efficacy News and Research

RSS

LEADLESS II study confirms positive benefits of St. Jude Medical’s Nanostim leadless pacemaker

St. Jude Medical, Inc., a global medical device company, today announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim™ leadless pacemaker for patients in need of a single-chamber ventricular pacemaker.

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Researchers at the University of Maryland and the University of Virginia have performed the first focused ultrasound treatments in the United States for dyskinesia associated with Parkinson's disease.

2 Sep 2015

HeartWare International signs definitive agreement to acquire Valtech

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that it has entered into a definitive agreement to acquire Valtech Cardio, Ltd.

2 Sep 2015

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Preoperative statins are associated with a 17% reduction in cardiac complications and a 43% reduction in mortality after noncardiac surgery, according to results from the VISION Study presented for the first time today at ESC Congress by Dr Otavio Berwanger, director of the Research Institute HCor, Hospital do Coração (Heart Hospital) in São Paulo, Brazil.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Temple-led study shows benefits of using digital health application for COPD patients

Early intervention facilitated by a digital health application for reporting symptoms of Chronic Obstructive Pulmonary Disease (COPD) provides key benefits for patients, according to the results of a Temple-led, two-year clinical study.

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Pie Medical Imaging receives 2015 European Frost & Sullivan Award for Technology Leadership

Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical Imaging (PMI) with the 2015 European Frost & Sullivan Award for Technology Leadership.

1 Sep 2015

Bioresorbable vascular scaffold shows similar safety, efficacy results compared to metal stent

A drug-eluting coronary stent, or "scaffold" made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.

1 Sep 2015

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.

1 Sep 2015

$Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction$

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

Gene transfer therapy aimed at correcting an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show.

1 Sep 2015

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

Freespira Breathing System now available for panic disorder treatment through Highmark Health's VITAL program

Highmark Health, Allegheny Health Network and Palo Alto Health Sciences have announced that the Freespira Breathing System is being made available to patients who suffer from panic disorder and symptoms of panic through Highmark Health's new VITAL Innovation Program.

1 Sep 2015

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

HIV-1 infection with multiple founder variants points to poorer clinical outcomes than infection with a single variant, according to a paper published today in the journal Nature Medicine.

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

New way to understand how transcranial magnetic stimulation can give relief for severe depression

A group of UK scientists have found a way of understanding how transcranial magnetic stimulation (TMS) can give relief to severely depressed patients. TMS is used as an alternative to Electro-Convulsive Therapy (ECT), but it is not known how it achieves its therapeutic effect. Understanding how it works may open the door to better, more targeted treatment for depression and other conditions.

31 Aug 2015

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.

31 Aug 2015

Efficacy News and Research

LEADLESS II study confirms positive benefits of St. Jude Medical’s Nanostim leadless pacemaker

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

HeartWare International signs definitive agreement to acquire Valtech

Preoperative statins linked to reductions in cardiac complications, mortality after noncardiac surgery

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Temple-led study shows benefits of using digital health application for COPD patients

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Pie Medical Imaging receives 2015 European Frost & Sullivan Award for Technology Leadership

Bioresorbable vascular scaffold shows similar safety, efficacy results compared to metal stent

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Freespira Breathing System now available for panic disorder treatment through Highmark Health's VITAL program

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

New way to understand how transcranial magnetic stimulation can give relief for severe depression

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News